Icatibant: a novel approach to the treatment of angioedema related to the use of angiotensin-converting enzyme inhibitors.
Am J Emerg Med
; 30(8): 1664.e1-2, 2012 Oct.
Article
em En
| MEDLINE
| ID: mdl-22100478
ABSTRACT
Angioedema related to the use of angiotensin-converting enzyme inhibitors (AE-ACEi) has, so far, been treated with antiallergic drugs with questionable results. Because angioedema in this setting is likely related to increased levels of bradikinin, we decided to use icatibant, a bradikinin receptor antagonist licensed for use in hereditary angioedema, in a patient with AE-ACEi. In the same patient, the time to resolution of the angioedema during previous attacks was about 2 days when classic antiallergic drug regimens were used; when icatibant was used, this time shortened to 10 hours. Icatibant is a promising drug in the treatment of AE-ACEi.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Bradicinina
/
Inibidores da Enzima Conversora de Angiotensina
/
Anti-Inflamatórios não Esteroides
/
Angioedema
Limite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Am J Emerg Med
Ano de publicação:
2012
Tipo de documento:
Article